Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow

Journal of Invasive Cardiology

Volumn 12, Issue 2, 2000, Pages 80-85

  Fugit, Michael D ^a,b   Rubal, Bernard J ^a   Donovan, Daniel J ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b DAVID GRANT MEDICAL CENTER   (United States)

Author keywords

Calcium channel blockers; Coronary blood flow; Intracoronary Doppler

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NICARDIPINE; VERAPAMIL;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INJECTION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY VESSELS; DILTIAZEM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NICARDIPINE; VERAPAMIL;

EID: 0034133523     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Babbitt DG, Perry JM, Forman MB. Intracoronary verapamil for reversal of refractory coronary vasospasm during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1988;12:1377-1381.
2. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995;75:849-850.
3. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
4. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
5. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
6. Jalinous F, Mooney JA, Mooney MR. Pretreatment with intracoronary diltiazem reduces non-Q wave myocardial infarction following directional atherectomy. J Invas Cardiol 1997;9:270-273.
7. Saito K, Nonogi H, Goto Y, et al. Anti-ischemic effect of intracoronary diltiazem on myocardial ischemia during PTCA. Heart Vessels 1996;11:92-99.
8. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997;30:1193-1199.
9. McIvor ME, Undemir C, Lawson J, Reddinger J. Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn 1995;35:287-291.
10. Henry PD. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol 1980;46:1047-1058.
11. Singh BN, Josephson MA. Clinical pharmacology, pharmacokinetics and hemodynamic effects of nicardipine. Am Heart J 1990;119:427-434.
12. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 1989;64:8H-15H.
13. Kaufmann P, Vassalli G, Utzinger U, Hess O. Coronary vasomotion during dynamic exercise: Influence of intravenous and intracoronary nicardipine. J Am Coll Cardiol 1995; 26:624-631.
14. Hanet C, Gurne L, Hue L, et al. Effects of intracoronary infusion of nicardipine during silent ischemia on myocardial metabolism and function. Eur Heart J 1988;9(Suppl N):145-150.
15. Vrolix MC, Sionis D, Piessens J, et al. Changes in human coronary flow reserve after administration of intracoronary diltiazem. J Cardiovasc Pharmacol 1991;18(Suppl 9):S64-S67.
16. Doucette JW, Corl D, Payne, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899-1911.
17. Labovitz AJ, Anthonis DM, Cravens TL, Kern MJ. Validation of volumetric flow measurements by means of a Doppler-tipped coronary angioplasty guide wire. Am Heart J 1993;126:1456-1461.
18. Ishihara M, Sato H, Tateishi H, et al. Effects of various doses of intracoronary diltiazem on coronary resistance vessels in humans. Jpn Circ J 1995;59:790-798.
19. Simonetti I, Trivella MG, Michelassi C, et al. Dose-response scrutiny of coronary vasodilation after intracoronary verapamil in man. A quantitative cineangiographic study. Eur Heart J 1986;7:848-858.
20. Ishihara M, Sato H, Tateishi H, et al. Effects of various doses of intracoronary verapamil on coronary resistance vessels in humans. Jpn Circ J 1996;61:755-761.
21. Rossen JD, Simonetti I, Marcus ML, et al. The effect of diltiazem on coronary flow reserve in humans. Circulation 1989;80:1240-1246.
22. Wheatley RM, Dockery SP, Kurz MA, et al. Interactions of nitroglycerin and sulfhydryl-donating compounds in coronary microvessels. Am J Physiol 1994;266:H291-H294.
23. Clarke B, Grant D, Patmore L, Whiting RL. Comparative calcium entry blocking properties of nicardipine, nifedipine and Py-10868 on cardiac and vascular smooth muscle (Abstr). Br J Pharmacol 1983;79:333P.
24. Bongrani S, Razzetti R, Schiantarelli P. Cardiovascular effects of nicardipine in anesthetized open-chest dogs in the absence and presence of β-adrenergic receptor blockade: A comparison with nifedipine and verapamil. J Cardiovasc Pharmacol 1985;7:899-905.
25. Pepine CJ, Lambert CR. Effects of nicardipine on coronary blood flow. Am Heart J 1988;116;248-254.
26. Lambert CR, Hill JA, Nichols WW, et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985;55:652-656.
27. Vrolix M, Piessens J. Specific coronary hemodynamic effects of nisoldipine and other vasoactive drugs. J Cardiovasc Pharmacol 1995;20(Suppl 5):S43-S48.
28. Whiting RL. Animal pharmacology of nicardipine and its clinical relevance. Am J Cardiol 1987;59:3J-8J.
29. Lambert CR, Pepine CJ. Nicardipine. In: Messerli FH (ed). Cardiovascular Drug Therapy. Philadelphia, Pennsylvania: W.B. Saunders Co., 1990: pp. 979-994.
30. Mueller RL, Scheidt S. Nitroglycerin. In: Messerli FH (ed). Cardiovascular Drug Therapy. Philadelphia, Pennsylvania: W.B. Saunders Co., 1990: pp. 865-876.
31. Cohen BM, Weber VJ, Blum RR, et al. Cocktail attenuation of rotational flow effects (CARAFE) study: Pilot. Cathet Cardiovasc Diagn 1996;3:69-72.
32. Magnon M, Gallix P, Cavero I. Intervessel (arteries and veins) and heart/vessel selectivities of therapeutically used calcium entry blockers: Variable, vessel-dependent indexes. J Pharmacol Exp Ther 1995:275:1157-1166.
33. Williams MS, Coller BS, Väänänen HJ, et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation 1998;98:742-748.
34. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-365.
35. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cordiol 1999;33:654-660.